Keith Pagnani, Co-head of S&C’s Healthcare & Life Sciences practice, appeared on “Capital Forum” to discusses the challenges and opportunities impacting medtech M&A with Stryker Chairman & CEO Kevin Lobo and Capital Forum host Jack Kalavritinos.
Keith said he’s optimistic that medtech M&A will rebound despite a recent slowdown. “M&A is always going to be in the toolbox,” he said. “If history is any indication, at the end of this cycle we’re going to see more tuck-in transactions, more divestiture of non-core assets and a focus on the core business,” Keith noted. “Over the long term I’m optimistic.”
S&C is a sponsor of the MedTech Conference, which will take place in Boston from October 24 to 26. Learn more and register here.
Watch Keith’s discussion of how the U.S. regulatory climate is affecting medtech M&A:
Watch Keith’s discussion of headwinds and opportunities in medtech M&A:
Sullivan & Cromwell’s Healthcare M&A Group
S&C’s Healthcare & Life Sciences Group has been at the forefront of healthcare M&A activity, bringing its creativity, culture of collaboration and deal prowess to advise an assortment of clients across the healthcare industry on some of the biggest and most significant matters.